Stimulant laxatives should be reserved for occasional use only
RECOMMENDATIONS: Patients You should not stop taking GLP-1 RAs without first consulting your health care professional, as stopping these medicines may worsen your condition
However, it significantly affects metabolic markers
Detailed conversion scenarios The following are detailed conversion scenarios of GLP-1 medications: Switching from liraglutide (Victoza/Saxenda) to semaglutide (Ozempic/Wegovy) Liraglutide is a daily injection, while semaglutide is administered once weekly
Each pack contains 4 Wegovy pens (1 for each week) *The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events, to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once-weekly dosage, or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age
Outlook Numerous compounds currently in development hold great promise for type 2 diabetes and obesity
